# Syndax Pharmaceuticals

Source: https://onco.cc/companies/syndax/  
OnCo record `syndax` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Syndax Pharmaceuticals, of Waltham, Massachusetts, developed revumenib (Revuforj), the first menin inhibitor approved for leukaemia, proved in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation. It also makes axatilimab for chronic graft-versus-host disease, and resistance mutations in menin itself are the class's unsolved problem.

## Summary

Syndax Pharmaceuticals, based in Waltham, Massachusetts, and listed as SNDX, developed revumenib, the first menin inhibitor approved for leukaemia. Revumenib, sold as Revuforj, was proved in the AUGMENT-101 trial in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, and the company also makes axatilimab, a CSF-1R antibody for chronic graft-versus-host disease. OnCo links it to acute myeloid leukaemia, to the revumenib drug record and to the AUGMENT-101 paper. Whether menin inhibitors move from relapsed disease into first-line combinations, and how the class handles resistance mutations in menin itself, are the open questions. Revumenib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Waltham, MA
- Type: biotech
- Website: https://www.syndax.com
- Ticker: SNDX

## Sources

- Official website: https://www.syndax.com

## Connected records

- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/)
- drugs: [Revumenib](https://onco.cc/drugs/revumenib/)
- trials: [AUGMENT-101](https://onco.cc/trials/augment-101/), [Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation](https://onco.cc/trials/nct07211958/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- key papers: [AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation](https://onco.cc/key-papers/paper-augment-101-revumenib-menin-nature-2023/)

---
JSON: https://onco.cc/api/v1/entities/syndax.json